Description
The Manual of Clinical Psychopharmacology has been the leading resource for the clinical use of psychiatric medications for more than 30 years. Now in its ninth edition, the manual continues to offer thoroughly updated, exhaustively vetted, and evidence-based information on psychotropic drugs in a collegial, conversational style that both training and practicing clinicians will find useful and authoritative. To ensure that the ever-expanding number of available agents with widening indications receives proper coverage, the authors have continued their effort to cull or condense coverage of less commonly used agents (e.g., barbiturates) in favor of more recently approved drugs (e.g., VMAT-2 inhibitors for tardive dyskinesia, pimavanserin) and those whose approval by the U.S. Food and Drug Administration (FDA) appears imminent. This approach has helped to maintain a user-friendly size, and the volume's logical structure makes information easy to locate on the fly, a boon to busy practitioners. The authors devote an entire chapter, new to this edition, to important developments in laboratory-guided pharmacotherapy, including pharmacogenomic testing, neurocognitive testing, quantitative EEG, and neuroimaging.
Its ease of use, accessible style, and evidence-based content have helped to elevate Schatzbergs Manual of Clinical Psychopharmacology to the well-deserved stature of a classic, which no mental health clinician should be without.